August 6, 2013. Charlottesville, VA. Martha Jefferson Hospital is pleased to be providing a new treatment option for men with advanced prostate cancer. Xofigo® (radium-223 dichloride) was approved by the Food and Drug Administration in May and is intended to be used in treatment for men whose prostate cancer has spread (or metastasized) to their bones.
“Being able to add Xofigo® to the list of treatment options for our patients further enhances the care we are able to provide our patients,” said Dr. Sylvia Hendrix, a radiation oncologist at Martha Jefferson. “This new drug allows us to deliver radiation directly to bone tumors by binding with minerals in the bone. By doing this, we can spare normal surrounding tissue from significant damage, which is a huge improvement from previous solutions.”
Dr. Charles Myers Jr, an oncologist with the American Institute for Disease of the Prostate, referred one of his patients to receive the first Xofigo® treatment at Martha Jefferson.
“Xofigo is a very important new treatment option for men with prostate cancer bone metastases. It is very effective at relieving bone pain and extends survival. It will allow many men to delay chemotherapy for a significant period of time," commented Dr. Myers.
Xofigo® is given once a month for six months and is injected into a patient’s vein over one minute. A typical appointment for treatment lasts no longer than fifteen minutes.
Sentara CarePlex Hospital, located in Hampton, VA, was the first facility in Virginia to treat a patient with Xofigo.
For more information on Xofigo®, call Martha Jefferson Health Connection at (434) 654-7009.